Maxime Dely: What if We Could Leukoreduce Without a Filter?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”What if we could leukoreduce without a filter?
When we talk about leukoreduction, we immediately think of leukocyte filters — disposable devices able to remove over 99% of white blood cells.
But… not everyone has access to them.
In some countries, the cost of this technology remains a major barrier to transfusion safety.
Yet there’s a simple, effective, and affordable alternative: the hard spin.
In many developing countries, the first step in whole blood processing is a soft spin.
This yields two main components:
- a PRP (platelet-rich plasma),
- and an RCC (red cell concentrate).
The issue? Around 90% of the residual white blood cells end up in the RCC.
And these cells can cause febrile non-haemolytic transfusion reactions, allergic reactions, and can even impair red cell storage quality.
By performing a hard spin, we create an interface between plasma and red cells — the well-known buffy coat.
That’s where most white cells accumulate.
The result?
A significant reduction in the residual leukocytes within the red cell concentrate — sometimes divided by 2, from 90% to 50% or even lower, depending on the separation and centrifugation settings.
The hard spin isn’t a miracle solution, but it’s a crucial first step toward safer transfusion, especially where resources are limited.
Because sometimes, innovation simply means doing better with what we have.”
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation